ArticlePsychotherapy and psychosomatics2025
Concomitant Psychotropic Medication Is Associated with Reduced Outcomes of Trauma-Focused Psychotherapy for Post-Traumatic Stress Disorder.
Article in Psychotherapy and psychosomatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPsychotropic medications are frequently prescribed alongside trauma-focused psychotherapy for post-traumatic stress disorder (PTSD), yet their impact on treatment response remains uncertain. This study emulated target trials to examine the association between psychotropic co-medication at treatment onset and psychotherapy outcomes in a real-world PTSD cohort.
methodsA prospective cohort of 6,125 adults with chronic or delayed-onset PTSD received a standardized 2-8 day trauma-focused psychotherapy program, including daily prolonged exposure and eye movement desensitization and reprocessing (EMDR) therapy, at a Dutch psychotrauma center (2021-2024). Target trial emulation with double machine learning with inverse probability of treatment weighting estimated the effects of specific psychotropic co-medications versus non-use on changes in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) scores (range, 0-80) from pre-to post-treatment.
resultsMean CAPS-5 scores improved by 25.7 points (Cohen's d = -2.30). Psychotropic co-medication (n = 1,382) was associated with reduced symptom improvement compared with non-use (model-estimated difference = -2.52 points; relative reduction = -9.4%, 95% CI = -10.0 to -8.9; d = -1.11, E = 10.0). This effect persisted at 6-month follow-up (d = -0.42). Antidepressants overall (d = -0.28; follow-up d = -0.56), amitriptyline (d = -0.51), and mirtazapine (d = -0.29) were consistently associated with poorer outcomes across sensitivity analyses. Similar patterns were observed for anticonvulsants, mood-stabilizing anticonvulsants, antipsychotics, fluoxetine, zolpidem, and zopiclone. Sensitivity analyses and E-values indicated robustness to unmeasured confounding.
conclusionSeveral psychotropic co-medications were associated with reduced outcomes of evidence-based trauma-focused psychotherapy for PTSD. By identifying this as a potentially modifiable factor, psychotherapy outcomes may be optimized. Trials are warranted to evaluate whether tapering or substituting these agents improves outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.